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Abstract 
Background 
Little is known about the population pharmacokinetics (PPK) of tacrolimus (TAC) in pediatric primary nephrotic 
syndrome (PNS). This study aimed to compare the predictive performance between nonlinear and linear PK 
models and investigate the significant factors of TAC PK characteristics in pediatric PNS. 
Methods 
Data were obtained from 71 pediatric patients with PNS, along with 525 TAC trough concentrations at steady 
state. The demographic, medical, and treatment details were collected. Genetic polymorphisms of CYP3A4*1G, 
CYP3A5*3, and ABCB1-C3435T were analyzed. The PPK models were developed using nonlinear mixed-effects 
model (NONMEM®) software. Two modeling strategies, linear compartmental and nonlinear Michaelis–Menten 
(MM) models, were evaluated and compared.  
Results 
Body weight, age, daily dose of TAC, co-therapy drugs (including azole antifungal agents and diltiazem), and 
CYP3A5*3 genotype were important factors in the final linear model (one-compartment model), whereas only 
body weight, co-therapy drugs, and CYP3A5*3 genotype were the important factors in the nonlinear MM model. 
Apparent clearance and volume of distribution in the final linear model were 7.13 L/h and 142 L, respectively. 
The maximal dose rate (Vmax) of the nonlinear MM model was 1.92 mg/day and the average concentration at 
steady state at half-Vmax (Km) was 1.98 ng/mL. The nonlinear model described the data better than the linear model. 
Dosing regimens were proposed based on the nonlinear PK model.  
Conclusion 
Our findings demonstrate that the nonlinear MM model showed better predictive performance than the linear 
compartmental model, providing reliable support for optimizing TAC dosing and adjustment in children with 
PNS. 
 
Keywords: Tacrolimus; children; primary nephrotic syndrome; population pharmacokinetic; nonlinear 
pharmacokinetics. 
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1 Introduction 
Tacrolimus (TAC), a calcineurin inhibitor (CNI), has been widely used as second-line therapy for the pediatric 
primary nephrotic syndrome (PNS), which is manifested by massive proteinuria, hypoalbuminemia, edema, and 
hypercholesterolemia (Atanda, 2012; Lombel et al., 2013; Kaku et al., 2015; Jahan et al., 2015; Chinese Medical 
Association, 2017). TAC has low oral bioavailability and is transported out of the intestine, liver, and kidney cells 
via the efflux pump p-glycoprotein (P-gp) encoded by the ABCB1. It is metabolized by a mixed-function oxidase 
system, primarily comprising the cytochrome P-450 system (CYP3A), and it binds strongly to erythrocytes, 
albumin, and alpha-1-acid glycoprotein (Venkataramanan et al., 1995). TAC has a narrow therapeutic window 
with a wide inter-individual pharmacokinetic (PK) variability and therefore, close therapeutic drug monitoring 
(TDM) and dosage individualization are recommended. 
Until recently, population pharmacokinetics (PPK) combined with the maximum a posteriori Bayesian (MAPB) 
estimation has been one of the classical methods to develop individualized dosing regimens (del Mar Fernández 
de Gatta et al., 1996; Fukudo et al., 2003; Woillard et al., 2017). The PPK of TAC has been extensively 
investigated in children after organ transplant, and the results have shown that body weight (Zhao et al., 2009; 
Musuamba et al., 2014; Prytuła et al., 2016; Andrews et al., 2018), CYP3A5*3 genetic polymorphisms (Guy-
Viterbo et al., 2014; Jacobo-Cabral et al., 2015; Prytuła et al., 2016; Andrews et al., 2018), and hematocrit (Zhao 
et al., 2009; Andrews et al., 2018) can partially explain the observed individual PK variability. However, so far, 
little is known about the TAC PK characteristics in children with PNS and the data in organ transplant patients 
might not be appropriate to extrapolate to patients with PNS, owing to the different pathological and physiological 
characteristics of PNS (Atanda, 2012). For example, gastrointestinal edema caused by hypoalbuminemia might 
affect the absorption of TAC and hypercoagulative state, one of the common complications of PNS, might change 
the distribution ratio of TAC in erythrocytes (Jahan et al., 2015). 
To the best of our knowledge, only three studies (Huang et al., 2018; Hao et al., 2018; Wang et al., 2019) have 
investigated the PK of TAC in children with PNS. Our previous study (Huang et al., 2018) conducted in 100 
children with PNS with 357 TAC trough concentrations showed that body weight, daily dose of TAC, and co-
therapy with azole antifungal agents significantly influenced the clearance of TAC. In the other two studies, Wang 
et al. described a TAC PPK model based on age and body weight, whereas Hao et al. found the CYP3A5*3 
genotype as a covariate besides body weight. It is worth noting that, these studies used a linear compartmental 
model, a traditional PK modeling strategy for TAC; however, a dose-dependent clearance of TAC was found in 
our previous study (Huang et al., 2018). These findings contradict the traditional viewpoint that TAC is a drug 
with linear PK, as described by 1- or 2- compartment model (Musuamba et al., 2014; Jacobo-Cabral et al., 2015; 
Prytuła et al., 2016; Andrews et al., 2018; Hao et al., 2018; Wang et al., 2019), but is similar to a recent study in 
which a superior predictability of nonlinear Michaelis–Menten (MM) model for TAC was found in adult renal 
transplant recipients (Zhao et al., 2016). 
We assumed that a nonlinear relationship might exist between dose and change in TAC steady-state PK. Disease 
status of pediatric PNS might result in nonlinear absorption or distribution process of TAC. For example, 
greater individual differences of oral bioavailability might occur when gastrointestinal edema exists in PNS. 
However, a linear model is inadequate to describe the absorption and distribution characteristic. Therefore, in this 
study, to the best of our knowledge, we adopted a nonlinear MM model for the first time to develop TAC PPK in 
pediatric PNS and then compared the results with those of the linear model. Furthermore, we included a higher 
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number of patients sampled at more than three dose levels than our previous study, in order to improve the 
accuracy of judgment of non-linearity (Ahn et al., 2005). 
Moreover, genetic polymorphism was not obtained in our previous study (Huang et al., 2018). The CYP3A5*3 
genotype was identified as an important factor affecting TAC PPK in children after organ transplant (Guy-Viterbo 
et al., 2014; Jacobo-Cabral et al., 2015; Prytuła et al., 2016; Andrews et al., 2018), which was also demonstrated 
in a previous study (Hao et al., 2018) mentioned above in children with PNS. Smaller TAC doses are usually 
required for CYP3A5*3/*3 carrier than for CYP3A5*1 carrier. In addition, due to the relatively high frequency of 
CYP3A4*1G in Chinese subjects, studies (Shi et al., 2011; Zuo et al., 2013) have also indicated that a combination 
genotype of CYP3A4*1/*1 and CYP3A5*3/*3 might be clinically important for TAC dose design in adult organ 
transplant recipients and that it could improve the efficacy and tolerability of TAC. Besides, gastrointestinal 
edema of PNS might affect the activity of P-gp existing in the gastrointestinal tract, and thus, ABCB1-C3435T 
alleles, which has also been mentioned in some studies in adult organ transplant recipients (Chan et al., 2004; Wu 
et al., 2011; Kravljaca et al., 2016), was also investigated in this study in addition to CYP3A5*3 and CYP3A4*1G. 
Therefore, this study was conducted to compare the difference between the nonlinear and linear models based 
on routine TAC TDM data obtained from our center and to screen factors influencing TAC PPK characteristics 
in children with PNS, in order to develop individualized dosage recommendations based on the superior model. 
 
2 Methods 
2.1 Patients and clinic data collection 
The concentrations of TAC in children with PNS were collected retrospectively from the medical records at the 
Children’s Hospital, Zhejiang University School of Medicine, China, from April 2011 to July 2017. Patients with 
PNS younger than 18 years old stabilized on the same dose of TAC for ≥ 3 days were included. Patients with 
serious infections or multiple organ injuries were excluded. Patients co-administered with traditional Chinese 
medicines that might affect TAC concentrations were also excluded. 
TAC was administered orally in the form of capsule (Prograf®, Astellas Ireland Co., Ltd. Killorglin, Co., Kerry, 
Ireland) every 12 hours. The initial dose of TAC was 50–150 µg/kg/day, which was later adjusted according to 
the routine TDM, clinical evidence of efficacy and adverse reactions. Complete records of actual body weight, 
height, age, gender, dosing history, sampling time, co-therapy drugs, and laboratory tests were also collected. The 
research had passed the ethical review of study hospital, and registered in Chinese Clinical Trial Registry 
(http://www.chictr.org.cn)(ID number: ChiCTR1900022943). 
2.2 Determination of TAC concentration 
Whole blood TAC concentrations were measured using an enzyme-multiplied immunoassay technique (Viva-
E automatic biochemical analyzer, Siemens Healthcare Diagnostics Inc., Erlangen, Germany; EMIT® 2000 
Tacrolimus Assay Kit, Siemens Healthcare Diagnostics Inc., Erlangen, Germany). Experimental procedures were 
conducted according to the manufacturers’ instructions (Viva-E System, 2014). The calibration range was 2.0–30 
ng/mL, and thus concentrations lower than 2.0 ng/mL were excluded. The inter- and intra-coefficients of variation 
for this assay were less than 10%. 
2.3 Genotyping 
Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood was collected and delivered to Shanghai 
Xiangyin Biotechnology Company (Shanghai, China) for DNA extraction, polymerase chain reaction, and 
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subsequent DNA sequencing (using the Snapshot technology, see Appendix 1 for details). The genotyping of 
three single-nucleotide polymorphisms, namely, CYP3A4*1G, CYP3A5*3, and ABCB1-C3435T, were performed. 
The allele frequency was confirmed using Hardy-Weinberg equilibrium. 
2.4 Population pharmacokinetic modeling 
Data were analyzed using the nonlinear mixed-effects model program (NONMEM®, Version 7.4; Icon Inc, PA, 
USA) compiled with gFortran (Version 4.9.2; http://www.gfortran.org). The output was explored by the R package 
(Version 3.3.1; http://www.r-project.org) and Xpose (Version 4.5.3; http://xpose.sourceforge.net). The first-order 
conditional estimation method with η–ε interaction (FOCE-I) was used throughout the model-building procedure. 
2.4.1 Base model 
Two modeling strategies, linear PK modeling and nonlinear modeling (MM model), were employed in the 
model development separately. The linear PK model was a one-compartment (CMT) model with the first-order 
absorption and first-order elimination and was parameterized in terms of apparent total clearance (CL/F), 
absorption rate constant (Ka), and apparent volume of distribution (Vd/F). Because of no sampling in the 
absorption phase, the Ka was fixed to 4.48 h-1 (Zhao et al., 2016). 
The MM model investigated was shown as below: 
MM model: Dose = 
VmaxCss
Km+Css
    (1) 
where Dose is oral dose of TAC. Css represents observed concentration at steady-state after at least 6 oral doses. 
Vmax represents maximal daily dose at steady-state, and Km represents an MM constant equal to the steady-state 
trough concentration at half-maximum daily dose. The MM model was written in the $PRED block in NONMEM®. 
Exponential models were used to account for between-subject variability (BSV) as below: 
Pi = TV (P) × exp (η)     (2) 
ŋ is defined as a symmetrically distributed, zero-mean random variable with a variance that is estimated as part 
of the model estimation.  
The following statistical models describing the residual unexplained variability (RUV) were investigated (Eqs. 
3-5): 
Y = IPRED + ε       (3) 
Y = IPRED × exp(ε)      (4) 
Y = IPRED × exp(ε1) + ε2        (5) 
where Y represents the observation, IPRED is the individual prediction, and εn represents the symmetrically 
distributed zero-mean random variables with variance terms that are estimated as part of the population model-
fitting process.  
2.4.2 Covariate models 
The potential covariates included age, gender, body weight, height, hematocrit, albumin, aspartate transaminase, 
serum creatinine, estimated glomerular filtration rate [calculated using Schwartz formula (Schwartz and Work, 
2009)], and co-therapy drugs, as well as genetic polymorphisms of CYP3A4*1G, CYP3A5*3, and ABCB1-C3435T. 
The daily dose of TAC was screened only for the linear model. Meanwhile, only the covariates with proportion > 
5 % in all patients were investigated. 
Body weight (WT) and age have significant impacts on the PK in pediatric patients. Therefore, physical 
maturation, which is a time-dependent process was considered at first. Four commonly used models based on 
allometric scaling were tested (Ding et al., 2015) (Eq. 6): 
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Pi = TV(P) × (
COV
COVmedian
)
  θ
× MF (6) 
where COVmedian is the median of the covariate, MF is the maturation factor that is defined as the process of 
becoming mature. The model displaying the best fit was selected for further analysis. 
Model I: In the simplest exponent model, the exponent θ was estimated, and MF was fixed to 1, indicating that 
maturation was not considered. This model is shown as Eq. 7: 
Pi = TV(P) × (
COV
COV𝑚𝑒𝑑𝑖𝑎𝑛
)
  θ
 (7) 
Model II: For the maturation model, the exponent θ was assigned a fixed value of 0.75, and MF was calculated 
according to Eq. 8: 
    MF = 
1
1+(
Age
TM50
)
Hill        (8) 
where TM50 is the age at which clearance maturation reaches 50% of that of adults, and Hill is the slope parameter 
for the sigmoid Emax maturation model. 
Model III: This is referred to as the WT-dependent exponent model (Eq. 9): 
θ = θ0 −
kmax × WT
Hill
k50
Hill＋WTHill
 (9) 
Model IV: This is referred to as the age-dependent exponent model (Eq. 10): 
θ = θ0-
kmax × Age
Hill
k50
Hill＋AgeHill
      (10) 
where θ0 is the value of the exponent at a theoretical WT of zero (Eq. 9) or at birth (0 years) (Eq. 10), kmax is the 
maximum decrease of the exponent, k50 is the WT (Eq. 9) or age (Eq. 10) at which a 50% decrease relative to the 
maximum decrease is attained. 
  Akaike information criteria (AIC) and Bayesian information criteria (BIC) was employed in the selection of 
the competing non-nested aforementioned models, which was calculated using Pirana software (version 2.9.0, 
http://www.pirana-software.com/) (Keizer et al.,2011). Models with lower values of AIC and BIC were regarded 
as superior. 
Continuous variables were investigated by linear models (Eqs. 11-12) or exponential model (Eq.13).  
 Pi = TV(P) + θ ×
COV
COVmedian
    (11) 
    Pi = TV(P) + θ × (COV − COV𝑚𝑒𝑑𝑖𝑎𝑛)      (12) 
Pi = TV(P) × (
COV
COVmedian
)
  θ
    (13) 
The categorical variables were investigated by scale model (Eq.14). 
Pi = {
 TV(P) × θ      if male   
 TV(P)          if female
              (14) 
where θ represents the degree of influence of covariate on the parameters, COV is value of a covariate for an 
individual and COVmedian is medium value or population typical value of covariate. 
The covariate model was built in a stepwise manner, with forward inclusion and backward elimination. In the 
forward inclusion analysis, a decrease in the objective function value (OFV) of at least 3.84 (2 test, P < 0.05, df 
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= 1) was used as a criterion for inclusion of the covariate in the model. An increase in the OFV of at least 6.63 (2 
test, P < 0.01, df = 1) was used as a criterion for retaining significant covariate-parameter relationships in the 
backward elimination step. The covariates in the model were also selected based on physiological plausibility of 
parameter estimates, goodness-of-fit plots, and statistical significance. 
2.4.3 Model Evaluation 
Prediction-based diagnostics and simulation-based diagnostics were used to compare the predictive 
performances of the linear model and non-linear model. 
Goodness-of-fit (GOF) was used. GOF include observed concentrations (OBS) versus population predicted 
concentrations (PRED), OBS versus individual predicted concentration (IPRED), conditional weighted residuals 
(CWRES) versus PRED and CWRES versus time after dose.  
Meanwhile, PRED and IPRED were estimated and compared with OBS by estimating the relative prediction 
error (PE%, Eq.15) and individual prediction error (IPE%, Eq.16), respectively. IF20 and IF30, which indicated the 
percentage of IPE that fell within the ± 20% and ± 30% range, respectively, were also applied to represent a 
combination index of both the accuracy and precision. 
  PE (%) = 
PRED−OBS
OBS
 × 100                (15) 
IPE (%) = 
IPRED−OBS
OBS
 × 100               (16) 
Nonparametric bootstrap (Ette et al., 1997) was employed to assess robustness of the model. 2000 bootstrap 
were performed using the Perl-speaks-NONMEM program (PsN, Version 4.8, http://psn.sourceforge.net). The 
median and the 2.5th-97.5th percentile intervals were calculated and compared with the values obtained using 
NONMEM®. 
Normalized prediction distribution errors (NPDEs) were also investigated. The dataset was simulated 2000 
times for NPDE, and the results were summarized graphically and statistically using the NPDE add-on package 
in R (Version 2.0, http://www.npde.biostat.fr/). NPDE results were summarized graphically using (1) quantile-
quantile plot of the NPDE, (2) a histogram of the NPDE, (3) scatter plot of NPDE versus time, and (4) scatter plot 
of NPDE versus PRED. If the predictive performance is satisfied, the NPDE will follow a normal distribution 
(Shapiro-Wilk test) with a mean value of zero (t-test) and a variance of one (Fisher’s test). 
2.5 Dosing regimen optimization  
  Monte Carlo simulations were carried out using the parameter estimates from the final PPK model. The aim 
was to determine the optimal starting dosing regimen and achieve the target Css of 5–10 ng/mL. Body weight of 
individual simulated was 10, 20, 30, 40, 50, 60, and 70 kg. One thousand simulations were carried out using the 
initial dataset and the Css of each simulated subject was calculated.  
Meanwhile, based on the actual bodyweight of patients for modelling, the TAC starting dose was calculated by 
two strategies: model-based estimation and empirical treatment in study hospital (50–150 µg/kg/day according to 
the recommendation of Chinese Medical Association). The predicted error of the model-based strategy was 
investigated (Eq.17):  
Predicted error (%) = 
Dmbs−Dets
Dets
 × 100              (17) 
where Dmbs represents the starting dose of the model-based strategy, Dets represents the starting dose from 
empirical treatment strategy.  
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3 Results 
3.1 Patient characteristics and gene allele frequency 
In total, data of 71 children with PNS were collected in this study, and 525 whole blood TAC concentrations 
were available for modeling. Forty patients were sampled at two TAC dose levels at least, and the mean dose 
levels were 1.9 ± 0.9 per patient. The mean dose of TAC was 1.5 ± 0.6 mg/day and the corresponding mean TAC 
trough concentration was 5.6 ± 2.9 ng/mL. Patient demographics and laboratory tests used for model development 
are summarized in Table 1. 
Genotype distribution and the allele frequency of CYP3A4/5 and ABCB1 are depicted in Table 2. There was no 
deviation from the Hardy-Weinberg equilibrium. The wild types of the CYP3A4*1G and ABCB1-C3435T genes 
were 64.8% and 33.8%, respectively. Patients with CYP3A5*1/*1, the wild type, was not be involved due to the 
low proportion (<5 %) in all patients; therefore, the covariate effect of CYP3A5*3 was focused on CYP3A5*1*3 
and CYP3A5*1*3 genotypes. 
3.2 Model Building 
3.2.1 Linear PK model 
A one-compartment (CMT) model with first-order absorption and elimination was employed to describe the 
linear PK of TAC. A residual model with the exponential method was chosen and the population typical value of 
CL/F and Vd/F in the base CMT model was 8.56 L/h and 202 L, respectively. In the forward inclusion step, by 
exploring the relationship of CL/F with body weight and age, the simplest allometric model (Model I) had lower 
AIC and showed the best fit. The daily dose of TAC and the combination of azole antifungal agents, diltiazem, 
and amlodipine were shown to have significant effects on the CL/F. In the backward elimination step, all the 
covariates remained in the final model except co-therapy with amlodipine. 
The CL/F and Vd/F in the final CMT model was 7.13 L/h and 142 L, respectively, for a 25-kg and 2-years old 
PNS pediatric patient with CYP3A5*3/*3 allele administrated with 1.5 mg/day. The final model for CL/F was 
listed as below: 
CL/F (L/h) = 7.13×(
𝐷𝐷
1.5
)0.225 × (
𝑊𝑇
25
)0.265 
×1.394 (if CYP3A5*1*3) 
×0.538 (if combined with azole antifungal agents) 
×0.88 (if combined with diltiazem)                   (18) 
where WT is the bodyweight and DD is the daily dose of TAC.  
It is noteworthy that when the daily dose of TAC was incorporated, the predictive performance of the final 
model obviously improved. A nonlinear positive correlation between the daily doses and CL/F showed that the 
higher the daily dose, the higher the CL/F. 
3.2.2 Michaelis–Menten model 
A combined model based on additive and exponential residual methods was chosen, and the population typical 
value of Vmax and Km in the base MM model were 1.8 mg·day-1 and 1.04 ng/mL, respectively. The correlations 
between Vmax and Km was considered, and the impact of all covariates were tested in Vmax and Km separately. Body 
weight was an important covariate for both Vmax and Km, and the simplest allometric model (Model I) was used. 
CYP3A5*3*3 genotype, co-therapy with azole antifungal agents and diltiazem also affected Km after the stepwise 
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screening. The Vmax and Km in the final MM model were 1.92 mg/day and 1.98 ng/mL, respectively. The final 
MM model was listed as below: 
Vmax (mg/day) = 1.92×(
𝑊𝑇
25
)0.559                               (19) 
Km (ng/mL) = 1.98×(
𝑊𝑇
25
)0.559   
×0.189 (if CYP3A5*1*3) 
×4.12 (if combined with azole antifungal agents) 
×2.01 (if combined with diltiazem)                     (20) 
 
3.3 Model evaluation  
The GOF plots indicated sufficient fit to the final models presented in Fig. 1. The final models showed no 
obvious bias or significant trends within these scatter plots, and the data fitting was considerably improved relative 
to that of the base model. Furthermore, the predictive performance of the models is presented as PE and IPE in 
the box plot (Fig. 2). The IF20 (85.5%) and IF30 (92.4%) of MM models reached > 80%, implying its superiority 
compared with < 70% of the CMT model (IF20 and IF30 was 47.2% and 68.4%, respectively). 
Table 3 shows the summary of the estimates obtained using the final CMT and MM models from bootstrap 
data. The two final models were stable, and the median values from the bootstrap procedure were close to the 
parameter estimates from the NONMEM, with < 5% bias. Meanwhile, the success rate determined using the 
bootstrap method of the MM model was 99.0%, higher than that of the CMT model (81.0%).  
The NPDE results are presented in Fig. 3. The assumption of a normal distribution for the differences between 
predictions and observations was acceptable. The quantile-quantile plots and histogram also confirmed the 
normality of the NPDE, indicating good predictability of the final MM model. 
3.4 Dosing regimens 
Due to the better predictive performance of the nonlinear MM model, a dosing algorithm (Table 4) for the 
starting dose of TAC was calculated based on the final established MM model:  
Dose = 
Vmax (final) Css
Km (final)+Css
                                      (21) 
where Vmax(final) represents Eq.19, and Km(final) represents Eq.20. 
The required dose can be calculated using the Vmax, Km, and the desired target trough concentration. For 
example, a CYP3A5*3*3 expresser weighing 20 kg without co-therapy of azole antifungal agent and diltiazem, 
can achieve a target steady-state trough concentration of 5–10 ng/mL, when the starting TAC dose ranged from 
1.26–1.47 mg/day. 
Meanwhile, Fig. 4 shows the predicted error of the TAC starting dose computed by MM model when compared 
to the empirical strategy. The mean value of predicted error was 10.8% with standard deviation of 12.23%, which 
indicated a stable predictability of proposed strategy in MM model. 
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4 Discussion 
TAC was considered to have linear kinetics in most of the previous studies. In this study, we also established a 
one-compartment linear PK model based on bodyweight, daily dose of TAC, CYP3A5*3 genotype, and co-therapy 
drugs. Interestingly, the incorporation of daily dose improved the predictive performance of the final model 
significantly. Consequently, our study aimed to explore a specific answer to the question of whether TAC steady-
state pharmacokinetics change with oral dose rate; therefore, a non-linear behavior of TAC PK in pediatric PNS 
patients was first determined and compared to the linear model.  
To the best of our knowledge, the MM model was an effective approach to describe the non-linear relationship 
of dose and steady state trough concentration. MM models in our study are data‐driven models that are not based 
on mammal compartment models. It is noteworthy that the MM model is a description of overall non-linearity, 
could one or several processes in PK, including absorption, distribution, metabolism, and excretion in vivo. Our 
finding is consistent with previous population analysis of tacrolimus in renal transplant patients (Zhao et al., 2016) 
and cyclosporine, another commonly used calcineurin inhibitor in renal transplant patients (Greve et al., 1993; 
Mao et al., 2018).  
In our present MM model, the typical value of Vmax in pediatric PNS was 1.92 mg/day (95% CI, 1.76-2.19 
mg/day), which indicated that the dose of TAC in excess of 1.92mg/day was likely to increase the concentrations 
unexpectedly. The typical value of Km in pediatric PNS was 1.98 ng/mL (95% CI, 0.77–2.11 ng/mL); that is, the 
nonlinearity of TAC will no longer influence dose rate adjustments when the Css was at or below 1.98 ng/mL. 
However, the values of Vmax and Km in pediatric PNS were significantly lower than those in adult renal transplant 
recipients (Vmax was 5.54 mg/day and Km was 2.36 ng/mL) (Zhao et al., 2016). The discrepancy in these two 
populations might be due to various changes during the growth of children (Yokoi, 2009) and higher target TAC 
trough concentrations in renal transplant patients [10–15, 8–15, and 5–12 ng/mL within 1, 1–3, and 3–12 months 
after transplantation, respectively (KDIGO Work Group, 2009)] than that in PNS patients [5–10 ng/mL] (Atanda, 
2012; Chinese Medical Association, 2017). 
We hypothesized that an important factor that contributes to the nonlinear process of TAC was the large 
absorption variability, a typical feature of TAC caused by its high lipophilicity and transportation out of the 
intestine via P-gp. Furthermore, when the gastrointestinal environment changes (for example, gastrointestinal 
edema in PNS or gastrointestinal dysfunction post organ transplantation), higher fluctuation in absorption 
saturation became more pronounced.  
The second possible explanation for the nonlinear PK of TAC might be the drug distribution complexity in 
children with PNS. Descending plasma protein binding rate caused by hypoalbuminemia of PNS might increase 
the proportion of free TAC; on the contrary, hypercoagulability, a common complication of PNS, might lead to 
higher TAC binding rate to erythrocytes, and then decrease the proportion of free TAC (Zahir et al.,2004; 
Golubović et al., 2014). However, the relationship between nonlinear PK and distribution in vivo could not be 
explained by the present study results, as albumin and hematocrit were not shown as significant variables in the 
established models.  
Moreover, the immature hepatic enzyme metabolism capability, relative liver weight, hepatic blood flow, and 
nutrition in children especially in infants younger than three years of age, might also attribute to the nonlinear 
metabolic process of TAC (Yokoi, 2009).  
In general, this interesting finding of MM model provides a novel perspective for future investigations; however, 
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considering that only trough samples were available, the function of daily dose might mostly reflect the non-
linearity of the clearance. Thus, further studies are needed to confirm the above assumptions and to explore the 
physiological significance of Vmax or Km.  
Both the linear and nonlinear models indicated that WT could significantly affect the PK of TAC in pediatric 
with PNS. Several structural models based on WT were tested in this study, and the maturation model best fit the 
data in the CMT model, whereas the allometric model for MM model. We also found that there was a positive 
correlation between WT and CL/For Vmax; therefore, a higher WT-normalized TAC dose was required as WT 
increased. 
The CYP3A5*3 genotype was identified as the most influential factor in all tested genetic polymorphisms in 
our study, in agreement with previously published data in pediatric and adult organ transplant patients (Shi et al., 
2011; Zuo et al., 2013; Guy-Viterbo et al., 2014; Jacobo-Cabral et al., 2015; Prytuła et al., 2016; Andrews et al., 
2018). Patients carrying CYP3A5*1*3 and CYP3A5*1*1 had a higher CL/F or Vmax than CYP3A5*3/*3 carriers 
with non-functional drug metabolic protein. Thus, CYP3A5*3 genotyping might be a useful approach for better 
prediction of individual TAC doses in pediatric PNS. For the low frequency of CYP3A5*1/*1 genotype among 
Chinese population (approximately 2.0–9.3% in previous reports (Shi et al., 2011; Zuo et al., 2013) and 2.7% in 
our study), a lower initial TAC dose should be recommended for patients in whom the CYP3A5 genotype is 
unknown. Dose recommendations in Table 4 might serve as a reference for TAC initial dose in children with PNS. 
In addition, the CYP3A4*1G and ABCB1 C3435T alleles, which were mentioned in some studies in adult organ 
transplant recipients (Wu et al., 2011; Shi et al., 2011; Zuo et al., 2013; Kravljaca et al., 2016), were not considered 
as important covariates in either linear or nonlinear model, as the incorporation of these two alleles could not 
improve the predictive performance of the final models.  
Co-medications also contributed to the difference in TAC PK in pediatric PNS. Azole antifungal agents, such 
as ketoconazole (Khan et al.,2014) and fluconazole (Guy-Viterbo et al., 2014) could inhibit the activity of 
intestinal and hepatic CYP3A enzymes and thus reduce TAC clearance, leading to a higher level of TAC 
concentration. Similarly, diltiazem, a benzothiazepine calcium channel blocker (CCB), is frequently used as a 
TAC-sparing agent (Jones and Morris, 2002; Li et al., 2011). However, amlodipine, another CCB used in our 
center for treating hypertension, was not considered to be a covariate in our final models. Several researchers 
(Passey et al., 2011; Storset et al., 2014; Lunde et al.,2014) regarded corticosteroids as an important factor; 
however, there was no difference with or without steroids in our study, probably because of the low dose of 
concomitant steroids (13.1 ± 10.7 mg/day presented as prednisone). 
There are some limitations to our study. First of all, for the retrospective property of this study, only trough 
concentrations were obtained; therefore, only CL/F and its covariate could be reliably assessed in the current study 
(Booth et al., 2003; Kowalski et al., 2001). Trough concentrations alone were not adequate to estimate Vd, which 
was also shown by the little between-subject variability estimation on Vd. For the same reason, it is hard to clear 
up what is the specific non-linear PK process. Secondly, the allele frequency of CYP3A5*1*1, the wild type, was 
very low in Chinese population, and high RSE was found when fixed the parameter of CYP3A5 *1 allele (CYP3A5 
*1*3/ CYP3A5 *3*3) as a covariate in the preliminary analysis of this study. Thirdly, parameter estimates for 
CYP3A5*1*3 and co-therapy of diltiazem showed high precision RSE, which may be attributable to insufficient 
information from the small patient size and sparse samples. Further investigation will be needed. 
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5 Conclusion 
TAC PK in children with PNS was first compared between the linear compartment and nonlinear models, and 
factors affecting individual PK variability were identified. MM model, the nonlinear model, described the PK 
behavior of TAC better than the linear model. Bodyweight, CYP3A5*3 genotypes, and co-therapy with azole 
antifungal agents and diltiazem were found to be significant in the final MM model, and dosing regimens were 
proposed. Further investigations are required to explore the nonlinearity of TAC. 
  
Table 1 Demographic data of pediatric PNS patients   
Characteristic  Mean ± SD Median (Range) 
Number of patients (Male/Female) 71 (51/20)  / 
Number of TAC samplings 525 / 
Age (years)  7.8 ± 3.7 7.3 (1.7-16.1) 
Body weight (kg) 28.4 ± 14.1 25.0 (10.0-83.0) 
Height (cm)  121.4 ± 23.1 118.0 (80.0-170.0) 
TAC daily dose (µg/kg/day)  59.8 ± 23.3 57.1 (6.4-160.0) 
TAC daily dose (mg/day) 1.5 ± 0.6 1.5 (0.25-4.0) 
TAC concentration (ng/mL)  5.6 ± 2.9 5.0 (2.0-29.2) 
TAC dose level per patient 1.9 ± 0.9 2.0 (1.0-4.0) 
Haematocrit (%)  41.6 ± 4.1 41.8 (19.1-52.4) 
Albumin (g/L) 27.8 ± 11.0 30.6 (7.9-54.6) 
Aspartate transaminase (U/L)  41.5 ± 21.0 37.0 (8.0-139.0) 
Serum creatinine (mol/L) 40.3 ± 16.2 38.5 (4.0-129.0) 
eGFR (mL/min/1.73 m2)  175.5 ± 90.5 154.1 (49.4-398.2) 
Co-therapy medications   
Corticosteroid a 71 (481) / 
Corticosteroid daily dose (mg/day) b 14.5 ± 11.0 10.0 (0.0-75.0) 
Calcium channel blockers   
Diltiazem a 17 (111) / 
Amlodipine a 9 (38) / 
Azole antifungal agent a 4 (15) / 
TAC, tacrolimus; eGFR, estimated glomerular filtration rate, calculated based on serum creatinine using 
the Schwartz formula as follow: eGFR = k × Height (cm) / Serum creatinine (mol·L-1), where k is a 
constant (for 1-12 years boys and >1 year girls , k is 49; and for >12 years boys, k is 62). 
a Presented as number of patients (samples)  
b Total daily prednisone dose, with methylprednisolone dose immerged after standardization 
 
 
  
Table 2 Allele frequencies of genetic polymorphisms in CYP3A4*1G, CYP3A5*3 and ABCB1-C3435T 
genes  
Genotypes Number of patients Percentage  
CYP3A4*1G (G20230A, rs2242480)   
GG (*1/*1) 46 64.8 % 
GA (*1/*1G) 21 29.6 % 
AA (*1G/*1G) 4 5.6 % 
CYP3A5*3 (A6986G, rs776746)   
GA (*1/*3) 26 36.6 % 
GG (*3/*3) 45 63.4 % 
ABCB1-C3435T (rs1045642)   
CC 24 33.8 % 
CT 38 53.5 % 
TT 9 12.7 % 
All frequencies were in agreement with those predicted by Hardy-Weinberg equation (P > 0.05) 
  
Table 3 Population pharmacokinetic parameter estimates of the base model, final model, and bootstrap 
Parameter 
Base model  Final model  Bootstrap of final model Bias 
(%) Estimate RSE (%)  Estimate RSE (%)  Median 2.5%-97.5% 
Linear one compartment model          
 OFV 1415.210   1265.676      
 ka (h-1) 4.48 /  4.48 /  4.48 / / 
 CL/F (L/h) 8.56 6.6  7.13 6.5  7.08 4.66-8.00 -0.70 
 CYP3A5*1*3 / /  0.394 24.1  0.393 0.209-0.620 -0.25 
 Body weight / /  0.265 32.3  0.267 0.122-0.481 0.75 
 Daily dose of tacrolimus / /  0.225 34.8  0.213 0.028-0.335 -5.33 
 Co-therapy with Azole antifungal agent / /  -0.462 6.1  -0.458 -0.548-(-0.212) -0.87 
 Co-therapy with diltiazem / /  -0.12 40.9  -0.125 -0.219-(-0.014) 4.17 
 Vd/F (L) 202 23.7        
 Between-subject variability          
 CL/F (%) 38.9 27.6  23.9 25.5  23.4 15.8-30.3 -2.09 
 Residual variability          
 Proportional error (%) 36.1 10.3  32.9 9.5  32.4 29.3-35.7 -1.52 
Nonlinear Michaelis-Menten model          
 OFV -661.967   -813.585      
 Vmax (mg/day) 1.8 5.7  1.92 4.4  1.92 1.76-2.19 0.00 
 Body weight / /  0.559 15  0.553 0.255-0.671 -0.51 
 Km (ng/mL) 1.04 26.3  1.98 17.9  1.97 0.77-2.11 0.00 
 CYP3A5*1*3 / /  0.189 38.1  0.183 1.42-9.78 -0.99 
 Body weight / /  0.559 15  0.553 0.255-0.671 0.00 
 Azole antifungal agent / /  3.12 9.7  3.12 (-0.55)-0.018 -1.07 
 Diltiazem / /  1.01 22.1  1.00 0.352-1.78 -0.51 
 Between-subject variability / /        
 Vmax (%) 35.2 19.7  20.4 21.2  20.0 14.8-24.3 -1.96 
 Km (%) 93.0 35.8  58.6 32.4  56.8 38.1-82.9 -3.07 
 Residual variability          
 Proportional error (%) 17.6 15.3  16.1 14.7  16.0 13.6-18.1 -0.62 
OFV, Objective function value; RSE, relative standard error; Bias% = (Bootstrap – NONMEM) / NONMEM × 100% 
Table 4 Dosing regimens based on non-linear model for the starting dose of tacrolimus with a target 
steady-state trough concentration (Css) of 5 ng/mL and 10 ng/mL. 
 
Weight 
(kg) 
Css 
(ng/mL) 
Dose (mg/day) 
CYP3A5*1*3 expresser  CYP3A5*3*3 expresser 
without co-
medications 
with co-
medications 
 without co-
medications 
with co-
medications 
10 5 1.10 0.84  0.93 0.39 
 10 1.15 0.97  1.05 0.59 
20 5 1.59 1.10  1.26 0.44 
 10 1.67 1.33  1.47 0.71 
30 5 1.96 1.26  1.48 0.46 
 10 2.08 1.58  1.78 0.77 
40 5 2.28 1.38  1.65 0.47 
 10 2.43 1.78  2.03 0.81 
50 5 2.55 1.48  1.79 0.49 
 10 2.73 1.94  2.24 0.85 
60 5 2.79 1.56  1.90 0.50 
 10 3.01 2.08  2.42 0.87 
70 5 3.01 1.62  2.00 0.51 
 10 3.26 2.20  2.58 0.89 
co-medications, azole antifungal agent and diltiazem 
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Fig. 1  
Goodness-of-fit plot for the (a) compartment model and (b) Michaelis-Menten model. DV, dependent variable; 
IPRED, individual prediction; PRED, population prediction; CWRES, conditional weighted residual; DD, daily 
dose.   
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Fig. 2  
Box plots of prediction error (%) and individual prediction error (%) of Michaelis-Menten (MM) final model 
and compartment (CMT) final model.  
  
 14 
 
 
 
Fig. 3  
NPDE of the two final models: (a) compartment model and (b) Michaelis-Menten model. NPDE, normalized 
predictive distribution error; PRED, population prediction; DD, daily dose. 
  
 15 
 
 
 
 
Fig. 4  
Predicted error of TAC starting dose estimated based on the final Michaelis−Menten model. 
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